POOLBEG PHARMA PLC

M&A Activity • Feb 21, 2025

National Storage Mechanism | Additional information

RNS Number : 9431X

Poolbeg Pharma PLC

21 February 2025

21 February 2025

Poolbeg Pharma plc

Termination of proposed combination with HOOKIPA Pharma Inc.

Further to the 2.4 announcement on 2 January 2025 on the potential combination of Poolbeg Pharma ("Poolbeg" or the "Company") and HOOKIPA Pharma Inc ("HOOKIPA"), the Board of Poolbeg announces that it was informed yesterday that HOOKIPA has terminated discussions on the proposed combination of the two companies.

Cathal Friel, Executive Chairman of Poolbeg, said: "We were surprised and disappointed to hear of HOOKIPA's decision to withdraw from the combination discussions. Throughout this process, we have seen strong interest in the potential of POLB 001 and we continue to be focused on maximising the potential of our in-house programmes and exploring new opportunities to generate value for our shareholders."

ENDS

Enquiries :
Poolbeg Pharma Plc	+44 (0) 207 183 1499
Cathal Friel, Chairman	ir@Poolbegpharma.com
Jeremy Skillington, CEO
Ian O'Connell, CFO
Cavendish Capital Markets Ltd  (Joint Financial Adviser and Rule 3 Adviser to Poolbeg, NOMAD & Joint Broker)	+44 (0) 207 220 0500
Corporate Finance Geoff Nash Henrik Persson Hamish Waller Trisyia Jamaludin   ​
Shore Capital (Joint Broker)	+44 (0) 207 408 4090
Corporate Advisory David Coaten Harry Davies-Ball
Corporate Broking Malachy McEntyre Isobel Jones
J&E Davy  (Joint Broker)	+353 (0) 1 679 6363
Anthony Farrell
Niall Gilchrist ​
Optimum Strategic Communications	+44 (0) 208 078 4357
Nick Bastin	Poolbeg@optimumcomms.com
Vici Rabbetts
Elena Bates

About Poolbeg Pharma plc 

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on acquiring, developing and commercialising innovative medicines that will help improve the lives of patients with rare and orphan diseases and where there is a high unmet medical need. Poolbeg comprises a strong and growing portfolio of development assets. For more information, please go to  www.poolbegpharma.com  or follow us on  Twitter  and  LinkedIn  @PoolbegPharma.

Forward-Looking Statements

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

SOAFZGZZGGFGKZZ